Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for the Company's pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as Immatics' partnerships with global leaders in the pharmaceutical industry. Immatics are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.